HeartFlow (HTFL) Q4 2025: Gross Margin Climbs 400bps as AI-Powered Plaque Revenue Accelerates

2026-03-18 | By EarningsIQ Research

HeartFlow’s Q4 results showcase a business rapidly scaling both revenue and margin through AI-driven product expansion and robust commercial execution. Plaque analysis adoption and the upcoming launch of PCI Navigator signal a step-change in platform breadth, while record gross margin and disciplined cost management reinforce the company’s path to profitability. Investors should focus on the pace of plaque ramp, utilization trends, and the durability of HeartFlow’s data-driven competitive moat as the company targets a much larger TAM in 2026 and beyond.

Summary

  • Plaque Revenue Inflection: Early adoption and payer coverage position plaque to become a major growth and margin driver.
  • AI Efficiencies Expand Margins: Autonomous processing and volume leverage drive gross margin toward new 85% target.
  • Commercial Model Scales: Installed base expansion and sticky physician adoption underpin high-visibility growth outlook.

Business Overview

HeartFlow is a medical technology company specializing in AI-powered cardiovascular diagnostics. The company generates revenue by providing non-invasive coronary artery disease assessment tools, primarily through its FFRCT, fractional flow reserve computed tomography, and plaque analysis solutions. Its business is anchored in two major segments: the mature FFRCT diagnostic platform and the rapidly scaling plaque analysis product, both sold to hospitals and clinics, with an expanding installed base in the U.S. and select international markets.

Performance Analysis

HeartFlow delivered a record quarter, with global revenue up over 40% year-over-year and gross margin reaching nearly 80%, a substantial improvement from the prior year. Growth was driven by a 53% increase in global case volume, fueled by robust FFRCT utilization and the rapid expansion of the installed base, which ended 2025 at 1,465 U.S. accounts. The plaque analysis business, though still early, contributed meaningfully and is expected to ramp sharply in the second half of 2026 as payer coverage and clinical adoption broaden.

Operating expenses grew at a slower pace than revenue, reflecting disciplined investment in salesforce expansion and R&D for the innovation pipeline. Operating leverage improved, with non-GAAP net loss narrowing year-over-year and strong cash reserves ($280 million) supporting continued growth investments. Notably, margin expansion was attributed to AI-driven process efficiencies and the increasing contribution of higher-margin plaque revenue, setting the stage for further profitability gains in coming years.

  • Plaque Adoption Accelerates: 489 plaque accounts at year-end, with payer coverage now at 75% of U.S. lives and strong initial Q1 volumes.
  • Installed Base Momentum: 340 new U.S. accounts added in 2025, the company’s largest annual expansion, driving predictable utilization ramp.
  • AI Drives Margin: Autonomous Processing and database scale underpin record gross margin, supporting new 85% midterm target.

HeartFlow’s commercial and operational execution is translating to high-visibility growth, with upside potential from the back-half plaque ramp and new product launches.

Executive Commentary

"We also achieved a record non-GAAP gross margin of nearly 80%, reaching our long-term target just over seven months from our IPO. Based on this momentum and our confidence entering the year, we're initiating full-year 2026 revenue guidance in the range of $218 million to $222 million."

John Farquhar, President and Chief Executive Officer

"The midpoints of our revenue and gross margin guidance imply approximately 31% gross profit growth in 2026. As John mentioned, we are also increasing our midterm non-GAAP gross margin target from 80% to 85%. This reflects high confidence in further AI-driven efficiencies driven by our autonomous processing initiative, scaling PLAC revenues, and continued volume leverage."

Vikram Virghese, Chief Financial Officer

Strategic Positioning

1. Plaque Analysis as a Growth Engine

Plaque analysis, AI-powered non-invasive plaque quantification, is transitioning from early adoption to a meaningful revenue and margin contributor. With 489 accounts live at year-end and payer coverage now spanning 75% of U.S. insured lives, HeartFlow expects plaque revenue to reach $15-17 million in 2026, heavily weighted to the second half as clinical experience deepens. The company frames plaque as a long-term driver with the potential to surpass FFRCT in revenue scale, supported by robust clinical validation and favorable reimbursement tailwinds.

2. AI and Data Moat

HeartFlow’s proprietary database of 160 million annotated CT images forms the backbone of its AI models and product innovation. The company asserts this dataset is unmatched in scale and diversity, underpinning both product accuracy and regulatory defensibility. The newly announced Autonomous Processing initiative leverages this data to automate intake, analysis, and output, with a human-in-the-loop quality check, supporting the ambitious 85% midterm gross margin target and providing a durable competitive moat against new AI entrants.

3. Commercial Expansion and Utilization Stickiness

The go-to-market model focuses on expanding the installed base and driving durable utilization. New accounts ramp to steady-state FFRCT usage within a year, and the majority maintain consistent order patterns. The commercial team added 340 new U.S. accounts in 2025, and the funnel for plaque accounts is robust, with management confident in reaching 1,000 plaque sites by year-end 2026. The company’s integration into hospital workflows and focus on medical education further entrench its platform within the standard of care.

4. Innovation Pipeline and TAM Expansion

PCI Navigator, an AI-driven planning tool for interventional cardiologists, launches in April 2026, extending HeartFlow’s reach into the cath lab and deepening its platform’s stickiness. The company is also targeting the high-risk asymptomatic population, a $6 billion incremental U.S. opportunity, with three randomized controlled trials planned over the next year. These initiatives expand HeartFlow’s total addressable market to $11 billion and position the company for long-term growth beyond its current core.

Key Considerations

This quarter marks a strategic inflection as HeartFlow leverages its data and AI assets to expand both product breadth and financial scale. The company’s execution on commercial adoption, payer wins, and innovation pipeline supports a high-confidence growth outlook, but the real test will be the pace and breadth of plaque adoption and the realization of margin targets as volume scales.

Key Considerations:

  • Plaque Ramp Timing: Most plaque revenue is expected in the second half; watch for signs of acceleration or delays in site activation and physician adoption.
  • AI-Driven Margin Expansion: Autonomous Processing and volume leverage are critical for reaching the new 85% midterm gross margin target.
  • Utilization Predictability: FFRCT utilization remains highly predictable, but plaque ramp is less mature and could see variability as clinical experience builds.
  • Reimbursement and Coverage: 75% U.S. coverage for plaque is a milestone, but further payer wins and pricing step-ups will be key for sustained ASP growth.
  • Competitive Moat: HeartFlow’s proprietary data, clinical evidence, and workflow integration are positioned as durable barriers, but ongoing innovation and regulatory vigilance are required.

Risks

Plaque adoption trajectory remains uncertain, with utilization and pricing still in early innings and dependent on physician education and clinical outcomes data. Competitive threats from new AI entrants, regulatory changes, or shifts in reimbursement could pressure both growth and margin. While HeartFlow’s data and workflow integration are strong moats, the rapid pace of AI innovation in healthcare warrants close monitoring. Execution risk around scaling new products and maintaining cost discipline as the business grows also remains a watchpoint.

Forward Outlook

For Q1 2026, HeartFlow expects:

  • Year-over-year revenue growth in excess of 30%, with sequential improvement of 1-2%.
  • Plaque revenue to remain modest in Q1, ramping in the back half of the year.

For full-year 2026, management guided to:

  • Total revenue of $218-222 million (24-26% growth)
  • Plaque revenue of $15-17 million, weighted to H2
  • Non-GAAP gross margin of 80-81%, with a new midterm target of 85%

Management emphasized:

  • High conviction in guidance, with upside potential if plaque adoption or PCI Navigator outperforms base assumptions.
  • Plaque revenue and gross margin expansion are expected to be strongest in the second half of 2026 as clinical catalysts and payer coverage compound.

Takeaways

HeartFlow’s Q4 performance and 2026 guide reflect a business executing on multiple strategic levers—commercial, innovation, and financial. The company’s ability to scale plaque revenue, drive AI-powered margin expansion, and deepen its clinical and data moat will determine the sustainability of its growth and profitability trajectory.

  • Plaque as a Catalyst: The success and pace of plaque adoption in the back half of 2026 will be the key swing factor for both revenue and margin upside.
  • AI Moat and Margin Expansion: Proprietary data and Autonomous Processing are translating to real financial leverage, but ongoing innovation and regulatory vigilance are required to defend the moat.
  • Future Watchpoints: Monitor plaque utilization trends, payer/pricing step-ups, and the impact of PCI Navigator on FFRCT volumes and platform stickiness.

Conclusion

HeartFlow exits 2025 with strong momentum, a rapidly expanding installed base, and a clear roadmap for AI-driven growth and margin expansion. The company’s execution on commercial, innovation, and clinical fronts supports its high-confidence outlook, but the real proof will be the scale and pace of plaque adoption and the realization of midterm margin targets.

Industry Read-Through

HeartFlow’s results underscore the accelerating adoption of AI-powered diagnostics in cardiovascular care, with payer coverage and clinical validation emerging as key gating factors for revenue and margin scale. The rapid expansion of installed base and integration into clinical workflows sets a high bar for new entrants, highlighting the importance of proprietary data and regulatory rigor in medtech AI. For peers in imaging, diagnostics, and digital health, the quarter signals that clinical evidence, reimbursement wins, and workflow integration are the critical levers to unlock durable growth as the industry shifts toward non-invasive, data-driven care pathways.

HTFL Healthcare Medical Technology AI Plaque Analysis Diagnostics Gross Margin Installed Base